Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 10, pp 1105–1111 | Cite as

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma

  • K. Okuda
  • H. SasakiEmail author
  • O. Kawano
  • H. Yukiue
  • T. Yokoyama
  • M. Yano
  • Y. Fujii
Original Paper

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial malignancies. In lung cancer cases, EGFR gene mutation at the kinase domain and EGFR gene amplification are reported to be predictors of the response to EGFR tyrosine kinase inhibitors. In malignant pleural mesothelioma (MPM), the role of EGFR is less clear. We studied EGFR gene mutation, amplification and protein expression in 25 Japanese patients with MPM. None had previously reported EGFR mutations detected by the TaqMan PCR assay. Using immunohistochemistry, 8/25 (32%) cases were positive for the EGFR protein. The cases of sarcomatous type and desmoplastic type were all negative. Fluorescence in situ hybridization analysis revealed three low polysomy cases and one high polysomy case. The low polysomy cases included one biphasic type and two epithelial types, and the high polysomy case was epithelial type. These four cases expressed EGFR protein. In MPM, EGFR seems to play a role in a limited subset of patients. To identify possible candidates for EGFR tyrosine kinase in inhibitor therapy, the information on the EGFR gene status may be valuable.

Keywords

Malignant pleural mesothelioma Epidermal growth factor receptor Amplification FISH Immunohistochemistry 

Notes

Acknowledgments

The authors would like to thank Mrs. Emi Sugiyama and Mariko Nishio for their excellent technical assistances.

References

  1. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375–1384PubMedCrossRefGoogle Scholar
  2. Cai YC, Roggli V, Mark E, Cagle PT, Fraire AE (2004) Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med 128:68–70PubMedGoogle Scholar
  3. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Hanev J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRefGoogle Scholar
  4. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970PubMedGoogle Scholar
  5. Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zou J, Schrump DS, Nguyan DM (2005) The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 129:1010–1017PubMedCrossRefGoogle Scholar
  6. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB (2006) Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118:521–522PubMedCrossRefGoogle Scholar
  7. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK (1990) Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61:924–926PubMedGoogle Scholar
  8. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207–215PubMedCrossRefGoogle Scholar
  9. Edwards JG, Swinson DE, Jones JL, Waller DA, O’Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54:399–407PubMedCrossRefGoogle Scholar
  10. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, Okumura M, Kawahara M, Sugiura H, Kuwabara Y, Fukai I, Matsumura A, Yano M, Kobayashi Y, Mizuno K, Haneda H, Suzuki E, Iuchi K, FujiiY (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50:375–384PubMedCrossRefGoogle Scholar
  11. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25:2406–2413PubMedCrossRefGoogle Scholar
  12. Govindan R, Kratzke RA, Herndon JE 2nd, Niehaus GA, Vollmer R, Watson D, Green MR, Kindler HL; Cancer and Leukemia Group B (CALGB 30101) (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11:2300–2304PubMedCrossRefGoogle Scholar
  13. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807PubMedCrossRefGoogle Scholar
  14. Hirsch FR, Varella-Garcia M, McCov J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowlev J, Gandara DR; Southwest Oncology Group (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23:6838–6845PubMedCrossRefGoogle Scholar
  15. Jänne PA, Taffaro ML, Salgia R, Johnson BE (2002) Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242–5247PubMedGoogle Scholar
  16. Kari C, Chan TO, Rocha de Quadros M, Rodeck U (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63:1–5PubMedGoogle Scholar
  17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  18. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286PubMedCrossRefGoogle Scholar
  19. Mukohara T, Civiello G, Johnson BE, Jänne PA (2005) Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 68:500–510PubMedCrossRefGoogle Scholar
  20. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:S9–S15PubMedCrossRefGoogle Scholar
  21. O’Byrne KJ, Edwards JG, Waller DA (2004) Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 45S:S45–S48CrossRefGoogle Scholar
  22. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kave FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  23. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4:215–222PubMedCrossRefGoogle Scholar
  24. Peto J, Hodgson JT, Matthews FE, Jones JR (1995) Continuing increase in mesothelioma mortality in Britain. Lancet 345:535–539PubMedCrossRefGoogle Scholar
  25. Peto J, Decarli A, La VC, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672PubMedCrossRefGoogle Scholar
  26. Price B (1997) Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145:211–218PubMedGoogle Scholar
  27. Rusch VW, Piantadosi S, Holmes EC (1991) The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102:1–9PubMedGoogle Scholar
  28. Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y (2005) EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11:2924–2929PubMedCrossRefGoogle Scholar
  29. Sasaki H, Shimuzu S, Endo K, Takada M, Kawahara M, Tanaka H, Matsumura A, Iuchi K, Haneda H, Suzuki E, Kobayashi Y, Yano M, Fujii Y (2006) EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118:180–184PubMedCrossRefGoogle Scholar
  30. Tsao MS, Sakurada A, Cutz JC, Zhu CO, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, MarranoP, da Cunha Santos G, Lagarde A, Richardson F, Sevmour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353:133–144PubMedCrossRefGoogle Scholar
  31. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Bover M, Emri S, Manegold C, Nivikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • K. Okuda
    • 1
  • H. Sasaki
    • 1
    Email author
  • O. Kawano
    • 1
  • H. Yukiue
    • 1
  • T. Yokoyama
    • 1
  • M. Yano
    • 1
  • Y. Fujii
    • 1
  1. 1.Department of Oncology, Immunology and SurgeryNagoya City University Graduate School of Medical ScienceNagoyaJapan

Personalised recommendations